The Impact of Time from Diagnosis to Initiation of Chemotherapy on Survival of Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma in the Veterans Health Administration
Diffuse large B-cell lymphoma (DLBCL) is the most common type of non-Hodgkin's lymphoma in adults representing approximately 30% of cases1 with an estimated annual incidence of 6-7 cases per 100,000 person-year in western countries and higher rates in males and older individuals2. The median age at diagnosis is in the mid-60s and 30% of patients are over 75 years of age1. The International Prognostic Index (IPI) is the primary clinical tool to predict outcomes estimating a 4-year PFS and a 4-year OS for patients with DLBCL.
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Gabriel Roman Souza, Zohra Nooruddin, Sophia Lee, Lauren Boyle, Kana Tai Lucero, Snegha Ananth, Kathleen Franklin, Michael Mader, Esteban Toro Velez, Amna Naqvi, Supreet Kaur Tags: Original Study Source Type: research
More News: Chemotherapy | Hematology | Leukemia | Lymphoma | Myeloma | Non-Hodgkin's Lymphoma | Study